perioperative results in equivalent groups of patients. CAS patients had better follow-up results in secondary restenosis and reinterventions; this fact, along with the not negligible rate of perioperative cranial nerve palsy in redo CEA patients, suggest a primary role for CAS in such a condition.
Objectives: Approaching tandem bifurcation and brachiocephalic disease using carotid endarterectomy (CEA) with ipsilateral proximal endovascular intervention (IPE) has been promulgated as safe and durable. There have been recent concerns regarding neurologic risk with this technique. The goal of this study was to define stroke and perioperative risk with this uncommon procedure across multiple centers.
Methods: Between August 2002 and July 2016, patients who underwent CEA+IPE were identified by operative records at three institutions. Primary end points were perioperative stroke and death, restenosis, freedom from neurologic event, and need for reintervention. Factors related to these end points were analyzed.
Results: A total of 62 patients (34 female [55%]) underwent CEA+IPE. Average age was 69 6 9 years, and 56 (90%) were on a statin and at least one antiplatelet agent. Bilateral internal carotid stenosis (>50%) was present in 32 (52%). A total of 26 patients (42%) were symptomatic, and 12 (19%) had undergone prior ipsilateral CEA. Bifurcation operations included longitudinal CEA/patch in 38 (61%), eversion CEA in 20 (32%), bypass graft in 3 (5%), and CEA/primary repair in 1 (2%). CEA was performed first in 53 (85%). All IPE included stenting, with a single stent used in 58 (94%). Balloon-expandable stents were placed in 51 patients (82%). Proximal arteries treated included the innominate (IA) in 20 (32%), left common carotid (CCA) in 32 (52%), right CCA in 8 (13%), and both the IA and right CCA in 2 patients (3%). IPE was protected by carotid cross-clamp in 48 (77%). Shunting occurred in 14 (23%). Four (6.5%) perioperative ipsilateral strokes and two hyperperfusion events occurred. There were three (4.8%) operative deaths (one from stroke, two cardiovascular). Combined neurologic event and death rate was 11.3%. Mean clinical follow-up was 6 6 4 years. Mean imaging follow-up was 3 6 4 years. Restenosis $50% at either intervention occurred in 20 (32%). Reintervention was performed for five proximal and three bifurcation failures (13%). Symptomatic status, redo operation, carotid-clamp protection, multiple stents, and procedural order were not associated with operative stroke. Carotid clamp protection was associated with less restenosis (P ¼ .003). Redo operation (P ¼ .04) and hyperlipidemia (P ¼ .05) were associated with reintervention. The 5-year actuarial survival was 81%. Stroke-free survival was 96% and freedom from reintervention was 86%.
Conclusions: Perioperative stroke and death with CEA+IPE is substantial. It is strikingly different than isolated CEA or CEA added to open brachiocephalic reconstruction. Restenosis is frequent, and reintervention at either the proximal stent or bifurcation is common. This technical strategy should be used cautiously and selectively reserved for those who are symptomatic with hemodynamically relevant tandem lesions and unfit for open revascularization. Objectives: Genetic testing to identify succinate dehydrogenase (SDH) mutations in patients with head and neck paraganglioma (HNP) has been in clinical practice for over a decade. However, recurrence and metachronous tumor occurrence risk in mutation-positive patients with HNP is not well studied.
Methods: Clinical and procedural details of consecutive patients treated for HNP from January 1996 to October 2016 were retrospectively reviewed. End points included tumor recurrence, metachronous tumor detection, and mortality. Patients were divided into three groups based on germline mutation testing: group I, positive; group II, negative; and group III, unknown/offered not tested.
Results: HNP was diagnosed in 268 patients; 214 who underwent excision were included (67 male, 147 female; mean age, 47 years). Directed genetic testing based on clinical presentation was offered to 89 and performed in 68 patients. Mutations in the SDH were detected in 69% (47 of 68); a majority being SDHD mutations. Group I: 47 patients underwent 64 procedures (81 tumors: 52 carotid body tumor [CBT]); of which 17 (36%) were bilateral, 7 (15%) multiple, 3 (6%) functional, and 7 (15%) malignant. Residual tumor was significant in two and minimal in eight. The former were managed by radiation therapy and reoperation. Local recurrence was detected in 12 (25%) at a median of 8 years and metachronous tumors in eight (17%) at a median of 13 years. Overall mortality was 4%. Six (13%) had more than one recurrence; 11 metachronous mediastinal and retroperitoneal paragangliomas were detected in eight patients (17%) and systemic metastases in five (10%). Group II: 21 patients underwent 22 procedures (23 tumors: 17 CBT). Two tumors (9%) were bilateral and two (9%) malignant. Excision was complete in all, with no reoperations, residual tumor, recurrence, or systemic metastasis at last follow-up. Group III: 146 patients underwent 153 procedures (156 tumors: 95 CBT). Seven (5%) were bilateral, 2 (1%) multiple, 8 (5%) functional, and 1 (0.6%) malignant. Local recurrence was detected in nine (6%) at a median time of 9 years and metachronous HNP in three (2%) at a median of 5 years (all had a strong family history). Systemic metastases occurred in two (1%); mortality was 3%. On survival analysis, the mutation-positive patients (group I) had 10-year overall, recurrencefree, and metachronous tumor-free survival rates of 93%, 69.4%, and 73%, respectively (P ¼ .0017).
Conclusions: Bilateral, functional, malignant, systemic, recurrent, and metachronous tumors are commoner in SDH mutation-positive patients with HNP. Overall survival in these patients is nearly normal, and metachronous tumors or recurrences occur late; long-term follow-up is necessary.
Author Disclosures: T. C. Bower: Nothing to disclose; R. R. DeMartino: Nothing to disclose; J. Johnstone: Nothing to disclose; M. Kalra: Nothing to disclose; J. Kasperbauer: Nothing to disclose; G. Oderich: Nothing to disclose; I. Sen: Nothing to disclose; W. Young: Nothing to disclose.
SS11.
Experience Objectives: This study presents our 26 years of experience managing patients with carotid body tumors (CBTs) and investigating the role of preoperative embolization (EMB) in surgical resection of CBTs.
Methods: The clinical data of CBT patients who underwent surgical resection at our institution from 1990 to April 2016 were retrospectively reviewed. Regression analyses were used to explore predictors of
